Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Estrogen can cause the growth of ovarian epithelial cancer cells. Hormone therapy
using fulvestrant may fight ovarian cancer by blocking the use of estrogen by the tumor
cells.
PURPOSE: This phase II trial is studying how well fulvestrant works in treating patients with
recurrent ovarian epithelial cancer.